All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
More information on our cookie policy.
BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Special reports
Artificial intelligence
Coronavirus
Diagnosing and tracking COVID-19
Drugs to Watch 2020
The next pandemic
Premium reports
BioWorld Financings Reports
Disease Forecast Reports
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Wednesday, April 14, 2021
Home
» FDA approves Lupkynis oral therapy for lupus nephritis
FDA approves Lupkynis oral therapy for lupus nephritis
Jan. 25, 2021
No Comments
Article reprints
Source:
https://science.bioworld.com/ddn/article.do?id=176084
BioWorld Science
Related Articles
FDA approves Ponvory as oral treatment for adults with relapsing multiple sclerosis
Pooled data from the AURORA and AURA-LV trials across lupus nephritis biopsy classes
